Sutro Biopharma posted Q2 Earnings of $‑2.94 per share, outpacing the $‑3.85 consensus by $0.91, indicating better-than-expected profitability. The beat reduces downside risk and supports the $19.05 stock, which has rallied 73.8% YTD, making the company more attractive to value‑oriented investors.

Key Highlights

  • STRO‑004 Phase 1 shows multiple partial responses across three tumor types with 6% discontinuation rate
  • Cash $164.3 million sustains operations into at least Q2 2028
  • Cash and marketable securities total $164.3 million, sufficient to fund operations through the second quarter of 2028.
  • Revenue fell to $9.8 million from $63.7 million year‑over‑year, but expenses declined to $39.5 million, delivering an EPS beat.

Cash and marketable securities stand at $164.3 million, enough to fund operations through the second quarter of 2028. Early Phase 1 data for the TF‑targeting ADC STRO‑004 revealed multiple partial responses and a favorable safety profile, underscoring the company’s advancing pipeline.

EPS Beat and Revenue Drop

Revenue of $9.8 million, driven largely by the Astellas collaboration, contrasts sharply with $63.7 million in the prior year, highlighting the transition from a revenue‑heavy baseline to a development‑focused model. Total R&D and G&A expenses declined to $39.5 million from $48.7 million, indicating disciplined spending amid a shrinking top line. Cash reserves of $164.3 million, though down from $202.6 million, remain ample for continued R&D. This earnings beat reduces immediate financial pressure and offers a buffer against the steep revenue decline.

STRO‑004 Phase 1 Early Activity

The STR IV E‑01 trial enrolled 49 patients across dose levels of 1-5 mg/kg within seven months, accelerating enrollment ahead of schedule. Dose optimization now focuses on 4-5 mg/kg, with the maximum tolerated dose still undefined. Clinical readouts show confirmed and ongoing partial responses in pancreatic, head‑and‑neck, and non‑small cell lung cancers, marking the first efficacy signals for a DAR8 exatecan ADC.

Safety data reveal a low discontinuation rate of 6%, with most adverse events being low‑grade nausea (33%), fatigue (29%) and anemia (18%). These results reinforce the platform’s claim of an expanded therapeutic index and suggest a competitive edge in heavily pretreated solid‑tumor populations.

Market Reaction and Valuation

Short interest sits at 11% of shares outstanding with 6.Peer performance on the day showed PALI down 4.4%, DMAC up 2.0% and ZNTL up 1.3%, indicating that Sutro’s movement outpaced sector peers. The combination of an EPS beat, strong cash position, and promising early trial data enhances the stock’s risk‑adjusted appeal, nudging value‑focused investors toward a potentially undervalued biotech play.

Upcoming Milestones

The next major data point arrives in the first half of 2027, when the company plans to update the STR IV E‑01 study with expanded cohort results, a catalyst that could validate the early efficacy signals. STRO‑006 is slated to begin a Phase 1 trial in Q3 2026, and the dual‑payload ADC STRO‑227 remains on schedule for IND submission later this year. The Astellas collaboration delivered a $10 million milestone in April 2026, and a second joint program is expected to enter the clinic by year‑end.

With $164.3 million in cash, the company is well positioned to fund these milestones without dilutive financing, keeping the runway intact through at least Q2 2028.

Peers Moving on This News